Free press releases distribution network?

Agency / Source: IMARC Group

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



IMARC Group Publishes New Report Analyzing the Potential of Therapeutic Monoclonal Antibodies in India - Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016” - IMARCgroup.com
IMARC Group Publishes New Report Analyzing the Potential of Therapeutic Monoclonal Antibodies in India

 

PRZOOM - /newswire/ - New Delhi, Delhi, India, 2013/04/11 - Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016” - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A huge patient pool, increasing prevalence of health insurance, strong biosimilar manufacturing capabilities and a largely unpenetrated market are expected to be the catalysts in driving the market for monoclonal antibodies in India. Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016”.

According to an analyst at IMARC Group,“India’s poor historical track record in Intellectual property protection has resulted in many Indian companies acquiring strong reverse engineering skills. The Indian generic industry provides generic drugs not only to India but to the entire world. India currently has more FDA approved manufacturing facilities than any other country outside the US. Globally there are only 2 approved biosimilar monoclonal antibodies with Reditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian generic manufacturer) being one of them. As a result, India and its biosimilar manufacturers can be regarded as the front runners in the global biosimilar antibody market race”.

Key Aspects Analyzed in this Report:

- Understanding the strengths, weaknesses, opportunities and challenges in the Indian monoclonal antibodies market

- Understanding the technological considerations and regulatory factors in the Indian monoclonal antibodies market
• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act
• Understanding the key regulations for registering, manufacturing and importing monoclonal antibodies in India

- Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe

- Comprehensive situation analysis of the Indian monoclonal antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroad.

Table of Contents

1 Market Definitions & Methodology
2 Executive Summary
3 Therapeutic Antibodies Market in India
3.1 Industry Analysis
3.1.1 Strengths
3.1.2 Weaknesses
3.1.3 Opportunities
3.1.4 Threats
3.2 Technological & Regulatory Assessment
3.2.1 Technological Assessment
3.2.2 Regulatory Assessment
3.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India
3.4 Market Analysis
3.4.1 Current & Future Sales Trends
3.4.2 Sales Breakup by Molecule
3.4.3 Sales by Indication
3.5 Evaluation of Top Monoclonal Antibodies
3.5.1.1 Avastin
3.5.1.2 Herceptin
3.5.1.3 Rituxan/Mabthera
3.5.1.4 Remicade
3.5.1.5 Humira
3.6 Biosimilar Case Studies
5.6.1 Reditux
5.6.2 Grafeel
3.7 Key Indian & Foreign Biosimilar Antibody Development Programmes.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IMARC Group Publishes New Report Analyzing the Potential of Therapeutic Monoclonal Antibodies in India

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From IMARC Group / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  Intrinsic Executive Search Ltd

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today